Search Press releases Keywords From To 1 Oct 2024 Transparency notification BlackRock, Inc. Read More 30 Sep 2024 Transparency notification BlackRock, Inc. Read More 30 Sep 2024 UCB announces a head-to-head study evaluating BIMZELX[®]▼(bimekizumab) versus SKYRIZI® (risankizumab) in active psoriatic arthritis Read More 27 Sep 2024 Transparency notification BlackRock, Inc. Read More 27 Sep 2024 UCB announces late-breaking two-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe hidradenitis suppurativa at EADV 2024 Read More 26 Sep 2024 Transparency notification BlackRock, Inc. Read More Pagination First page Previous page Previous … Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Page 12 Page 13 Page 14 … Page 10 of 69 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
